peterschreiber.media Piper Sandler upgraded Neurocrine Biosciences (NASDAQ:NBIX) to overweight, stating it sees the company’s schizophrenia drug candidate NBI-1117568 as still…
Read More »peterschreiber.media Piper Sandler upgraded Neurocrine Biosciences (NASDAQ:NBIX) to overweight, stating it sees the company’s schizophrenia drug candidate NBI-1117568 as still…
Read More »